CAMBRIDGE, Mass., Aug. 24, 2020 /PRNewswire/ -- Leap Therapeutics,
Inc. (Nasdaq: LPTX), a biotechnology company focused on developing
targeted and immuno-oncology therapeutics, today announced the
expansion of its leadership team with the appointment of
Jason S. Baum, Ph.D., as Vice
President, Head of Translational Medicine and Christine M. Granfield as Vice President, Head
of Regulatory Affairs and Quality.
"It is my pleasure to welcome Jason and Chris to the team," said
Douglas E. Onsi, President and Chief
Executive Officer of Leap. "Their expertise in the development and
approval of novel therapies will prove invaluable as we advance our
DKN-01 monoclonal antibody as a treatment for patients with
multiple biomarker-defined cancers. We are excited to have them
join us to lead and build out these critical functional areas."
Dr. Baum joins Leap with more than a dozen years of industry
experience. Most recently, he served as Executive Director and
Precision Medicine Leader, General Medicine and Lung Cancer with
Novartis Oncology Precision Medicine. Prior to joining Novartis,
Dr. Baum held various positions of increasing responsibility with
Merrimack Pharmaceuticals, including as Director, Head of
Diagnostics and Biomarkers. He started his career as a Product
Scientist with Cell Signaling Technology. Dr. Baum holds a Ph.D. in
Molecular Biology, Cell Biology and Biochemistry and an M.A. in
Biology from Boston University. He
holds a B.A. in Biology from Colgate
University.
Ms. Granfield joins Leap with more than 25 years of industry
experience. Prior to joining Leap, she served as an independent
regulatory consultant with Granfield Associates LLC. Previously,
she was Senior Director, Regulatory Affairs with Novartis
Corporation Oncology Business Unit, where she led the development
of regulatory strategy and submissions for companion diagnostics
supporting various oncology personalized medicine programs. Prior
to her position with Novartis, Ms. Granfield served as Senior
Director, Regulatory Affairs with Genzyme Corporation. She also
held positions with Boston Scientific Corporation. Ms. Granfield
has a BSE, Biomedical Engineering from The
Catholic University of America and is a member of the
Regulatory Affairs Professional Society.
About Leap Therapeutics
Leap Therapeutics (Nasdaq:LPTX) is focused on developing
targeted and immuno-oncology therapeutics. Leap's most advanced
clinical candidate, DKN-01, is a humanized monoclonal antibody
targeting the Dickkopf-1 (DKK1)
protein, a Wnt pathway modulator. DKN-01 is in clinical trials in
patients with esophagogastric, hepatobiliary, gynecologic, and
prostate cancers. Leap has formed a partnership with BeiGene, Ltd.
for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New
Zealand. For more information about Leap Therapeutics, visit
http://www.leaptx.com or view our public filings with
the SEC that are available via EDGAR at
http://www.sec.gov or via
https://investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include Leap's expectations with
respect to the development and advancement of DKN-01, including the
initiation, timing and design of future studies, enrollment in
future studies, potential for the receipt of future option
exercise, milestones or royalty payments from BeiGene, and other
future expectations, plans and prospects. Although Leap believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, forward-looking statements are
subject to known and unknown risks, uncertainties and other factors
that could cause actual results to differ materially from our
expectations. Such risks and uncertainties include, but are not
limited to: that the initiation, conduct, and completion of
clinical trials, laboratory operations, manufacturing campaigns,
and other studies may be delayed, adversely affected, or impacted
by COVID-19 related issues, the accuracy of our estimates regarding
expenses, future revenues, capital requirements and needs for
financing; the outcome, cost, and timing of our product development
activities and clinical trials; the uncertain clinical development
process, including the risk that clinical trials may not have an
effective design or generate positive results; our ability to
obtain and maintain regulatory approval of our drug product
candidates; the size and growth potential of the markets for our
drug product candidates; our ability to continue obtaining and
maintaining intellectual property protection for our drug product
candidates; and other risks. Detailed information regarding factors
that may cause actual results to differ materially will be included
in Leap Therapeutics' periodic filings with the SEC,
including Leap's Annual Report on Form 10-K for the fiscal year
ended December 31, 2019, as filed with
the SEC on March 16, 2020 and as may be updated
by Leap's Quarterly Reports on Form 10-Q and the other reports we
file from time to time with the SEC. Any forward-looking
statements contained in this release speak only as of its date. We
undertake no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
Contact:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Heather Savelle
Investor Relations
Argot Partners
212-600-1902
heather@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-expands-leadership-team-with-addition-of-two-industry-veterans-301116610.html
SOURCE Leap Therapeutics, Inc.